GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioAdaptives Inc (OTCPK:BDPT) » Definitions » Capex-to-Operating-Cash-Flow

BioAdaptives (BioAdaptives) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is BioAdaptives Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

BioAdaptives's Capital Expenditure for the three months ended in Mar. 2024 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was $-0.04 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


BioAdaptives Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for BioAdaptives's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAdaptives Capex-to-Operating-Cash-Flow Chart

BioAdaptives Annual Data
Trend Dec13 Dec14 Dec15 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - - - - -

BioAdaptives Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioAdaptives's Capex-to-Operating-Cash-Flow

For the Packaged Foods subindustry, BioAdaptives's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioAdaptives's Capex-to-Operating-Cash-Flow Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioAdaptives's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioAdaptives's Capex-to-Operating-Cash-Flow falls into.



BioAdaptives Capex-to-Operating-Cash-Flow Calculation

BioAdaptives's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.224
=N/A

BioAdaptives's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.041
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioAdaptives  (OTCPK:BDPT) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


BioAdaptives Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BioAdaptives's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


BioAdaptives (BioAdaptives) Business Description

Traded in Other Exchanges
N/A
Address
2620 Regatta Drive, Suite 102, Las Vegas, NV, USA, 89128
BioAdaptives Inc is engaged in investigating, marketing and distributing natural plant- and algal-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. The human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. Its product lines include PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore.
Executives
Richard Chiang other: Previous Officer and Director 460 BRANNAN STREET SUITE 78064, SAN FRANCISCO CA 94107
Barry Epling director 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Ferris Holding Inc. 10 percent owner 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Gerald Epling director, officer: Pres, CEO, Secretary, CFO 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128

BioAdaptives (BioAdaptives) Headlines

From GuruFocus

BioAdaptives Sponsors COVID-19 Long Hauler Survey

By GuruFocusNews GuruFocusNews 07-02-2022

BioAdaptives Sponsors COVID-19 Long Hauler Survey

By GuruFocusNews GuruFocusNews 06-22-2022